Federal contract award
75N93023C00048
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541512 — Computer Systems Design Services |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $6.9M |
| Current contract value | $6.9M |
| Potential contract value / ceiling | $6.9M |
| Start date | Sep 30, 2023 |
| Current end date | Sep 30, 2026 |
| Potential end date | Sep 30, 2026 |
| Latest award activity | Apr 24, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Apr 24, 2026 | P00005 | $-26 | FY26 UDO INITIATIVE: EOI::EO: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING: EOI BILATERAL MODIFICATION TO DESCOPE FOR FY2025 COST SAVINGS: "ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCIN |
| Sep 29, 2025 | P00004 | $2.0M | EOI::EO: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING: EOI BILATERAL MODIFICATION TO DESCOPE FOR FY2025 COST SAVINGS: "ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES" |
| Jul 9, 2025 | P00003 | $0 | ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES |
| Sep 10, 2024 | P00002 | $1.1M | ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES |
| Jun 25, 2024 | P00001 | $2.3M | ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES |
| Sep 12, 2023 | 0 | $1.4M | ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.